Toxoplasmosis Treatment Market by Type, Route of Administration, Distribution Channel, and Geography: Forecast up to 2027

Toxoplasmosis is an infection caused due to a common parasite, which is present in cat feces and in contaminated food. This parasite is referred as Toxoplasma gondii. The symptoms of toxoplasmosis disease are headache, body aches and pain, fever, fatigue, and swollen lymph nodes. Apart from this, the people with weakened immune system who receive chemotherapy, a preceding toxoplasma infection may arise and cause the symptoms such as confusion, poor coordination, headache, and seizures. The growing prevalence of toxoplasmosis is the key factor propelling the market growth. The incidence of toxoplasmosis is on the rise, majorly owing to the rise in the number of people with low immune systems, such as cancer patients, HIV/AIDS patients, and transplant recipients. This is propelling the demand for effective treatments for the disease. In addition to this, the rise in awareness about foodborne illness accelerates the growth of toxoplasmosis treatment market. On the other hand, the negative effects of the drugs may negatively impact the toxoplasmosis treatment market growth. The Toxoplasmosis Treatment Market is expected to grow at a rate of 4.3% CAGR by 2027.

Toxoplasmosis Treatment Market by Type

• Acquired Toxoplasmosis
• Congenital Toxoplasmosis

Toxoplasmosis Treatment Market by Route of Administration

• Oral
• Parenteral

Toxoplasmosis Treatment Market by Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

Toxoplasmosis Treatment Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

As in the Toxoplasmosis Treatment market for type is segmented into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment has acquired a significant share in the market. This is due to the increase in incidence of parasitic infection which causes acquired toxoplasmosis. Further, the congenital toxoplasmosis segment is anticipated to register highest CAGR over the forecast period.

On the basis of route of distribution segmentation the Toxoplasmosis Treatment market is bifurcated into Oral and Parenteral. Compared to parenteral, the oral segment dominated the market with highest share. This can be attributed to the increased adoption of oral drugs owing to noninvasive, high patient compliance, easy to handle, and does not need any specific sterile conditions.

In terms of distribution channel, the market is divided into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The hospital pharmacies segment holds the maximum share of the market. The maximum share of the segment is ascribed to the availability of toxoplasmosis drugs and increase in number of hospital pharmacies to treat the toxoplasmosis disease.

In accordance to the regional analysis, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to lead the market due to the presence of leading players, increase in government initiatives, well-developed healthcare infrastructure, and rise in occurrence of cancer disease which causes toxoplasmosis.

In addition, the healthcare organizations, governments, and non-profit organizations across the world are working to raise awareness regarding the dangers of toxoplasmosis disease and the prominence of early diagnosis and treatment. This is resulting in more people looking for medical attention and accelerating the demand for effective treatments. Thus, the rising awareness regarding the toxoplasmosis disease is vitally driving the global market growth. Apart from this, the increase in chemotherapy procedures can result in growth in number of toxoplasmosis infection, therefore, this highlights the requirement for the toxoplasmosis treatment for the patient, leading to the growth of the market.

Prominent players of the toxoplasmosis treatment market are Teva Pharmaceutical Industries Limited, Mangalam Drugs and Organics Ltd., Zorish Healthcare Private Limited, Alvogen, Dr Reddy's Laboratories Ltd., Vyera Pharmaceuticals LLC, Oakrum Pharma, Kaiser Permanente, omicron pharmaceuticals, and Manus Aktteva Biopharma LLP.

Henceforth, now-a-days the trend of pets in home is rising highly which leads to the increased pets related diseases among humans. Thus, this factor is majorly leading to the increased occurrence of toxoplasmosis disease in humans which eventually contributes to growth of the market growth.

Key reasons to purchase the report:

• This study represents the key manufacturers, presenting of sales, revenue, market size and new developments for major players.
• This study analyzes the global and key geographical regions market prospective and advantages, opportunities and challenges, constraints and risks.
• This report further depicts the important trends, drivers, impacting factors of the toxoplasmosis treatment
• This report represents the competitive outlook in terms of expansions, agreements, new product launches and acquisitions in the toxoplasmosis treatment